Figure 2.

Investigator-assessed clinical benefit rate at week 24 by subgroup (intent-to-treat [ITT] population). *No. includes both treatment arms together. ^†Time from initial diagnosis of breast cancer to initial diagnosis of locally advanced or metastatic breast cancer. ABC = advanced breast cancer; BRCA1/BRCA2 = breast cancer susceptibility gene 1 or 2; CI = confidence interval; CNS = central nervous system; DFI = disease-free interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HER2− = human epidermal growth factor receptor 2-negative; HR+ = hormone receptor-positive; PCT = physician’s choice of chemotherapy; TNBC = triple-negative breast cancer; y = years.